ADT for Prostate Cancer Does Not Boost Cardiovascular Mortality

Share this content:

Use of short-course androgen deprivation therapy (ADT) may improve overall and disease-specific survival but does not appear to increase cardiovascular mortality in men with clinically-localized prostate cancer, according to Boston researchers. John Schieszer has the latest on the story in today's Medical Minute.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters